Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MPI Clear all
Withdrawn Phase 4 Interventional

The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion

NCT01655524
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ASSUAGE Protocol
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 3, 2026, 8:12 PM EDT
Recruiting No phase listed Observational

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

NCT04199000
View directory record Official record
Conditions
Congenital Disorders of Glycosylation
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
12
States / cities
San Diego, California • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 3, 2026, 8:12 PM EDT
Terminated No phase listed Observational

Automated Myocardial Performance Index Using Samsung HERA W10

NCT04140669
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome, Congenital Diaphragmatic Hernia, Neural Tube Defects, Lower Urinary Tract Infection
Interventions
Automated Myocardial Performance Index (MPI)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Not applicable Interventional Results available

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

NCT04316676
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
Diagnostic Test · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 3 Interventional

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 3, 2026, 8:12 PM EDT
Not listed No phase listed Observational

Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography

NCT01150578
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
No intervention
Drug
Lead sponsor
Aiden Abidov
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 3, 2026, 8:12 PM EDT
Completed No phase listed Observational

Dynamic Cardiac SPECT Imaging

NCT01934985
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 3, 2026, 8:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Control & the Functional Organization of the Frontal Cortex

NCT06436209
View directory record Official record
Conditions
Multitasking Behavior and Neural Representations Associated With Multitasking Ability, Healthy Volunteers, Executive Function
Interventions
Multitask Practice Intervention (MPI), Single-task Practice Intervention (SPI)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 3 Interventional

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208312
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 3, 2026, 8:12 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 3, 2026, 8:12 PM EDT
Not listed Phase 1 Interventional

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240537
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
Interventions
Sargramostim, BB-MPI-03, Montanide
Drug
Lead sponsor
Benovus Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

NCT01618669
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Drug · Procedure
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
60
States / cities
Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

NCT01347710
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
73
States / cities
Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Topical SLPI on Skin Wounds

NCT00005569
View directory record Official record
Conditions
Healthy, Wound Healing
Interventions
SLPI (Secretory Leukocyte Protease Inhibitor)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:12 PM EDT
Not listed Phase 2 Interventional

Chemotherapy in Treating Patients With Liver Cancer

NCT00003044
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 8:12 PM EDT
Not listed No phase listed Observational

The Value of CT-FFR Compared to CCTA or CCTA and Stress MPI in Low to Intermediate Risk ED Patients With Toshiba CT-FFR

NCT03329469
View directory record Official record
Conditions
Coronary Artery Disease, Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction
Interventions
Toshiba CT-FFR
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Results available

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486
View directory record Official record
Conditions
Coronary Artery Disease, Type 1 Diabetes Mellitus
Interventions
Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casinomacropeptide and Satiety

NCT01587911
View directory record Official record
Conditions
Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions
Whey, Whey-CMP, Control, CMP, MPI, CPI
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)

NCT00468325
View directory record Official record
Conditions
Coronary Angiography, Chest Pain
Interventions
Multi-slice Computed Tomography, Rest-stress Nuclear Myocardial Perfusion Imaging
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
25 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Weston, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2009 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Not applicable Interventional

Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain

NCT00705458
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris, Unstable Angina, Acute Coronary Syndrome
Interventions
Coronary Computed Tomography Angiography, Stress Nuclear Myocardial Perfusion Imaging
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 3, 2026, 8:12 PM EDT
Terminated Phase 3 Interventional

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

NCT00380198
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Timeline
2006
U.S. locations
42
States / cities
Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 3, 2026, 8:12 PM EDT
Enrolling by invitation No phase listed Observational

The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

NCT07761728
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 3, 2026, 8:12 PM EDT